Patents Assigned to Astellas Pharma Inc.
  • Publication number: 20230059753
    Abstract: Object: To provide an antisense guide RNA for editing a target RNA by ADAR. Solution: An antisense guide RNA for editing a target RNA by ADAR, containing at least one functional region and an antisense region that is complementary to a portion of the target RNA and can form a double strand with the target RNA, in which the at least one functional region is linked to the antisense region, and in which the guide RNA does not substantially contain an ADAR-recruiting base sequence.
    Type: Application
    Filed: December 8, 2020
    Publication date: February 23, 2023
    Applicant: Astellas Pharma Inc.
    Inventors: Eiji YOSHIMI, Yukari MORIYA, Mariko MANDA, Takayasu GOTOH, Takatomo ARAI
  • Patent number: 11578067
    Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 14, 2023
    Assignees: KYOTO UNIVERSITY, ASTELLAS PHARMA INC.
    Inventors: Shimon Sakaguchi, Naganari Ohkura, Norihisa Mikami, Shuh Narumiya, Masahiko Akamatsu, Guliang Xia, Hironori Harada, Naoto Nakamura, Satoru Ujihara, Hisao Hamaguchi
  • Publication number: 20230000965
    Abstract: An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.
    Type: Application
    Filed: December 1, 2020
    Publication date: January 5, 2023
    Applicants: ASTELLAS PHARMA INC., RIKEN
    Inventors: Ayaka AKIBA, Tatsuya OKUDAIRA, Yasuhide MASUHARA, Keisuke OHSUMI, Shinichiro FUJII
  • Patent number: 11541127
    Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: January 3, 2023
    Assignees: Astellas Pharma, Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs
  • Publication number: 20220379171
    Abstract: An exercise support device (10) includes: an acquisition unit (11A) that acquires a physical quantity indicating an execution degree of an exercise according to an exercise program indicating a predetermined self-weight exercise; a deriving unit (11B) that derives subsequent intensity of the exercise by using the physical quantity acquired by the acquisition unit (11A); and a presentation unit (11C) that presents the intensity derived by the deriving unit (11B).
    Type: Application
    Filed: October 20, 2020
    Publication date: December 1, 2022
    Applicant: Astellas Pharma Inc.
    Inventor: Motohiro KANAYAMA
  • Publication number: 20220356207
    Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 10, 2022
    Applicants: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima University
    Inventors: Hideki ENDO, Yukihito ISHIZAKA, Akira ISHIGURO, Tomoki TAKASHINA, Takashi YAMAMOTO, Tetsushi SAKUMA
  • Patent number: 11473071
    Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 104, 105, 135, 141, 153, 167, or 172 in the expression regulatory region of human Utrophin gene are expected to be useful for treating or preventing DUCHENNE muscular dystrophy or BECKER muscular dystrophy.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: October 18, 2022
    Assignees: ASTELLAS PHARMA INC., MODALIS THERAPEUTICS CORPORATION
    Inventors: Eiji Yoshimi, Katsuro Yoshioka, Tetsuya Yamagata, Yuanbo Qin, Iain Robert Thompson, Nidhi Khanna
  • Publication number: 20220275359
    Abstract: [Problem to be Solved] To provide a guide RNA. [Solution] A guide RNA for editing a target RNA sequence, comprising an antisense nucleotide sequence complementary to a portion of the target RNA sequence, a short-chain ADAR-recruiting nucleotide sequence, and at least one functional nucleotide sequence.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 1, 2022
    Applicants: Astellas Pharma Inc., Fukuoka University
    Inventors: Eiji YOSHIMI, Yukari MORIYA, Mariko MANDA, Masatora FUKUDA
  • Patent number: 11414456
    Abstract: The present application provides a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: August 16, 2022
    Assignees: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima University
    Inventors: Hideki Endo, Yukihito Ishizaka, Akira Ishiguro, Tomoki Takashina, Takashi Yamamoto, Tetsushi Sakuma
  • Publication number: 20220233721
    Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcriptional repressor, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 127, SEQ ID NO: 46, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 88, SEQ ID NO: 91, SEQ ID NO: 133, SEQ ID NO: 137, SEQ ID NO: 117, or SEQ ID NO: 119 in an expression regulatory region of a human DMPK gene, are expected to be useful for treating muscular dystrophy.
    Type: Application
    Filed: May 27, 2020
    Publication date: July 28, 2022
    Applicants: Astellas Pharma Inc., Modalis Therapeutics Corporation
    Inventors: Eiji YOSHIMI, Tomoya OE, Tetsuya YAMAGATA, Keith M. CONNOLLY
  • Patent number: 11395852
    Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: July 26, 2022
    Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbH
    Inventors: Ugur Sahin, Özlem Türeci
  • Patent number: 11390652
    Abstract: It is intended to provide a fusion polypeptide that regulates the transcription of a target gene. The present inventors have provided a fusion polypeptide comprising: a cell-penetrating peptide; a DNA-binding polypeptide; and a transcriptional regulator.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: July 19, 2022
    Assignees: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima University
    Inventors: Hideki Endo, Yukihito Ishizaka, Takashi Yamamoto, Tetsushi Sakuma
  • Patent number: 11376328
    Abstract: Provided is a pharmaceutical composition in which the solubility and/or dissolution properties of a poorly-soluble drug can be improved. The pharmaceutical composition comprises a poorly-soluble drug, and polyvinyl alcohol having a saponification degree of 63 mol % or more and 67 mol % or less.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 5, 2022
    Assignee: Astellas Pharma Inc.
    Inventors: Takatsune Yoshida, Hiroyuki Kojima, Yoshiaki Umemoto, Sachie Namiki, Akira Takagi, Ken Shimada
  • Patent number: 11344589
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: May 31, 2022
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Takafumi Nakamura, Hajime Kurosaki, Motomu Nakatake
  • Publication number: 20220143263
    Abstract: Provided is a thrombin-carrying hemostatic sheet that is suitable for hemostasis during surgery, in particular, for hemostasis during spine surgery, that is convenient without preparation before use, and that is bioabsorbable and can be embedded in the body as it is. The hemostatic sheet is composed of a gelatin sponge carrying an effective amount of thrombin, wherein (A) the density is 30 to 55 mg/cm3, and (B) the shape maintaining angle in wet conditions is 55 to 120°.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 12, 2022
    Applicants: Astellas Pharma Inc., National University Corporation Tokyo Medical and Dental University
    Inventors: Makoto OGINO, Keiichi YOSHIHARA, Yasuharu KIMURA, Megumi AOKI, Toshitaka YOSHII, Satoru EGAWA
  • Patent number: 11312966
    Abstract: [Problem] To provide a nucleic acid expected to be useful for treating mite allergy. [Means to be solved] Provided is a nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleic acid comprises a nucleotide sequence encoding a signal peptide, a nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP, a nucleotide sequence encoding an allergen domain comprising Der p 1, Der p 2, Der p 23, and Der p 7, a nucleotide sequence encoding a transmembrane domain and a nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP in this order.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: April 26, 2022
    Assignee: Astellas Pharma Inc.
    Inventors: Takanori Marui, Masao Uchida
  • Patent number: 11286459
    Abstract: An object of the present invention is to provide an animal cell culture method which is high in protein productivity. Provided is a method for culturing animal cells in a culture medium, wherein the culture medium comprises a nucleic acid component(s) (deoxyuridine, thymidine, and/or deoxycytidine, or a salt(s) thereof). Also provided is a method for producing a protein, the method comprising the step of culturing animal cells expressing the protein in a culture medium, wherein the culture medium comprises a nucleic acid component(s).
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: March 29, 2022
    Assignee: Astellas Pharma Inc.
    Inventors: Yasuhiro Takagi, Takuya Kikuchi
  • Publication number: 20220089455
    Abstract: [Problem] A novel method for producing a nanoparticle having a metal particle which contains iron oxide to which one or more hydrophilic ligands are coordination bonded is provided, where the nanoparticle is useful as a contrast agent for magnetic resonance imaging. [Means for Solution] As the novel method for producing a nanoparticle having a metal particle which contains iron oxide to which one or more hydrophilic ligands are coordination bonded, by performing ligand exchange to a hydrophilic ligand from an iron oxide nanoparticle having a surface to which a hydrophobic ligand is coordination bonded in one step using a phase transfer catalyst, it is possible to expect shortening of production processes and reduction of hydrophilic ligands used. Furthermore, by producing an iron oxide nanoparticle having a surface to which a hydrophobic ligand is coordination bonded using a dropwise addition method, it is possible to avoid a rapid temperature rise and a reaction at a high temperature of 200° C.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 24, 2022
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Takashi KIKUCHI, Tsuyoshi MIZUTANI, Hiroki TOYA, Akio KURODA, Yota GOTO, Shun HIRASAWA, Toshiyuki SUGIMORI
  • Patent number: 11279757
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: March 22, 2022
    Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige Gmbh
    Inventors: Rita Mitnacht-Kraus, Stefan Wöll, Korden Walter, Özlem Türeci, Ugur Sahin
  • Patent number: RE49111
    Abstract: [Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic M3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: June 21, 2022
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Taisuke Takahashi, Takanori Koike, Kenji Negoro, Hiroaki Tanaka, Jun Maeda, Kazuhiro Yokoyama, Hajime Takamatsu